

DATI PERSONALI

Cognome e Nome: Durigutto Paolo
E-mail: pdurigutto(at)units.it
ORCID: 0000-0003-3862-4970

STUDI

Ha conseguito il **diploma di Laurea in Scienze Biologiche** presso l'Università di Trieste il 19/07/2002 con la votazione 97/110, presentando una tesi sperimentale in Immunologia dal titolo “*Sviluppo e caratterizzazione di un modello sperimentale di artrite da immunocomplessi complemento mediata: studio di un anticorpo scFv contro il quinto componente complementare*”.

Nel gennaio 2003 ha superato l'esame per l'abilitazione alla professione di biologo.

ATTIVITA' SCIENTIFICA

Da Ottobre 2000 a Luglio 2002: tesi sperimentale presso il Dip. di Scienze della Vita (prima Dip. Di Fisiologia e Patologia), Università di Trieste, Lab di Immunologia, supervisore Prof. Francesco Tedesco.

Da Luglio 2002 a Dicembre 2017: biologo presso il Dip. di Scienze della Vita (prima Dip. Di Fisiologia e Patologia), Università di Trieste, Lab di Immunologia, supervisori Prof. Francesco Tedesco e Prof. Paolo Macor.

Da Gennaio 2018 a Dicembre 2024: biologo presso il Laboratorio Sperimentale Ricerche Immunologia Clinica e Reumatologia, Istituto Auxologico Italiano - IRCCS Milano, supervisori Prof. Francesco Tedesco, Prof. Paolo Macor e Prof. Pierluigi Meroni.

.

PUBBLICAZIONI SU RIVISTE INTERNAZIONALI

β 2GPI-targeted polymeric nanoparticles form a protective layer to prevent vascular thrombosis in an anti-phospholipid syndrome model.

Durigutto P, Grimaldi MC, Bozzer S, Raschi E, Meroni P, Tedesco F, Macor P.

Front Immunol. 2025 Feb 27;16:1520619. doi: 10.3389/fimmu.2025.1520619. eCollection 2025.

PMID: 40083554

Idarubicin-loaded chitosan nanobubbles to improve survival and decrease drug side effects in hepatocellular carcinoma.

Mossenta M, Argenziano M, Capolla S, Busato D, Durigutto P, Mangogna A, Polano M, Sblattero D, Cavalli R, Macor P, Toffoli G, Dal Bo M.

Nanomedicine (Lond). 2025 Feb;20(3):255-270. doi: 10.1080/17435889.2025.2452154. Epub 2025 Jan 15.
PMID: 39815170

A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma.

Busato D, Capolla S, Durigutto P, Mossenta M, Bozzer S, Sblattero D, Macor P, Dal Bo M, Toffoli G.

J Transl Med. 2023 Nov 28;21(1):864. doi: 10.1186/s12967-023-04745-9. PMID: 38017492

Plasminogen activator-coated nanobubbles targeting cellbound β 2-glycoprotein I as a novel thrombus-specific thrombolytic strategy.

Macor P, Durigutto P, Argenziano M, Smith-Jackson K, Capolla S, Di Leonardo V, Marchbank K, Tolva VS, Semeraro F, Ammollo CT, Colucci M, Cavalli R, Meroni P, Tedesco F.

Haematologica. 2023 Jul 1;108(7):1861-1872. doi: 10.3324/haematol.2022.281505. PMID: 36172817

Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients.

Macor P, Durigutto P, Mangogna A, Bussani R, De Maso L, D'Errico S, Zanon M, Pozzi N, Meroni PL, Tedesco F.

Biomedicines. 2021 Aug 12;9(8):1003. doi: 10.3390/biomedicines9081003. PMID: 34440207

Multi-organ complement deposition in COVID-19 patients. (not peer reviewed)

Macor P, Durigutto P, Mangogna A, Bussani R, D'Errico S, Zanon M, Pozzi N, Meroni P, Tedesco F.

medRxiv. 2021 Jan 8:2021.01.07.21249116. doi: 10.1101/2021.01.07.21249116. Preprint. PMID: 33442701

Complement Activation and Thrombin Generation by MBL Bound to β 2-Glycoprotein I.

Durigutto P, Macor P, Pozzi N, Agostinis C, Bossi F, Meroni PL, Grossi C, Borghi MO, Planer W, Garred P, Tedesco F.

J Immunol. 2020 Sep 1;205(5):1385-1392. doi: 10.4049/jimmunol.2000570. Epub 2020 Aug 5. PMID: 32759297

Targeting CD34+ cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis.

Colombo F, Durigutto P, De Maso L, Biffi S, Belmonte B, Tripodo C, Oliva R, Bardini P, Marini GM, Terreno E, Pozzato G, Rampazzo E, Bertrand J, Feuerstein B, Javurek J, Havrankova J, Pitzalis C, Nuñez L, Meroni P, Tedesco F, Sblattero D, Macor P.

J Autoimmun. 2019 Sep;103:102288. doi: 10.1016/j.jaut.2019.05.016. Epub 2019 Jun 15.

New insight into antiphospholipid syndrome: antibodies to β 2glycoprotein I-domain 5 fail to induce thrombi in rats.

Durigutto P, Grossi C, Borghi MO, Macor P, Pregnolato F, Raschi E, Myers MP, de Groot PG, Meroni PL, Tedesco F.

Haematologica. 2019 Apr;104(4):819-826. doi: 10.3324/haematol.2018.198119. Epub 2018 Nov 15.

Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?

Meroni PL, Borghi MO, Grossi C, Chighizola CB, Durigutto P, Tedesco F.

Nat Rev Rheumatol. 2018 Jul;14(7):433-440. doi: 10.1038/s41584-018-0032-6. Review.

Targeted Delivery of Neutralizing Anti-C5 Antibody to Renal Endothelium Prevents Complement-Dependent Tissue Damage.

Durigutto P, Sblattero D, Biffi S, De Maso L, Garrovo C, Baj G, Colombo F, Fischetti F, Di Naro AF, Tedesco F, Macor P.

Front Immunol. 2017 Sep 6;8:1093. doi: 10.3389/fimmu.2017.01093. eCollection 2017.

Clq acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation.

Bulla R, Tripodo C, Rami D, Ling GS, Agostinis C, Guarnotta C, Zorzet S, Durigutto P, Botto M, Tedesco F.

Nat Commun. 2016 Feb 1;7:10346. doi: 10.1038/ncomms10346.

Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery.

Meroni PL, Macor P, Durigutto P, De Maso L, Gerosa M, Ferraresso M, Borghi MO, Mollnes TE, Tedesco F.

Blood. 2016 Jan 21;127(3):365-7. doi: 10.1182/blood-2015-09-672139. Epub 2015 Dec 7

Critical Role and Therapeutic Control of the Lectin Pathway of Complement Activation in an Abortion-Prone Mouse Mating.

Petitbarat M, Durigutto P, Macor P, Bulla R, Palmioli A, Bernardi A, De Simoni MG, Ledee N, Chaouat G, Tedesco F.

J Immunol. 2015 Dec 15;195(12):5602-7. doi: 10.4049/jimmunol.1501361. Epub 2015 Nov 11.

Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice.

Macor P, Secco E, Mezzaroba N, Zorzet S, Durigutto P, Gaiotto T, De Maso L, Biffi S, Garrovo C, Capolla S, Tripodo C, Gattei V, Marzari R, Tedesco F, Sblattero D.

Leukemia. 2015 Feb;29(2):406-14. doi: 10.1038/leu.2014.185. Epub 2014 Jun 6.

A non complement-fixing antibody to $\beta 2$ glycoprotein I as a novel therapy to control abortions and thrombosis in antiphospholipid syndrome.

Agostinis C, Durigutto P, Sblattero D, Borghi MO, Grossi C, Guida F, Bulla R, Macor P, Pregnolato F, Meroni PL, Tedesco F.

Blood. 2014 May 29;123(22):3478-87. doi: 10.1182/blood-2013-11-537704. Epub 2014 Mar 18.

Prevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5.

Durigutto P, Macor P, Ziller F, De Maso L, Fischetti F, Marzari R, Sblattero D, Tedesco F.

PLoS One. 2013;8(3):e58696. doi: 10.1371/journal.pone.0058696. Epub 2013 Mar 7.

Orchestration of Inflammation and Adaptive Immunity in Borrelia burgdorferi-Induced Arthritis by Neutrophil-Activating Protein A.

Codolo G, Bossi F, Durigutto P, Bella CD, Fischetti F, Amedei A, Tedesco F, D'Elis S, Cimmino M, Micheletti A, Cassatella MA, D'Elis MM, de Bernard M.

Arthritis Rheum. 2013 May;65(5):1232-42. doi: 10.1002/art.37875.

Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5.

Macor P, Durigutto P, De Maso L, Garrovo C, Biffi S, Cortini A, Fischetti F, Sblattero D, Pitzalis C, Marzari R, Tedesco F.

Arthritis Rheum. 2012 Aug;64(8):2559-67. doi: 10.1002/art.34430.

In vivo distribution of β 2 glycoprotein I under various pathophysiologic conditions.

Agostinis C, Biffi S, Garrovo C, Durigutto P, Lorenzon A, Bek A, Bulla R, Grossi C, Borghi MO, Meroni P, Tedesco F.

Blood. 2011 Oct 13;118(15):4231-8. Epub 2011 Jul 26.

Innate immunity, through late complement components activation, contributes to the development of early vascular inflammation and morphologic alterations in experimental diabetes.

Fischetti F, Candido R, Toffoli B, Durigutto P, Bernardi S, Carretta R, Tedesco F, Fabris B.

Atherosclerosis. 2011 May;216(1):83-9. Epub 2011 Mar 1.

Mannose-binding lectin is produced by vaginal epithelial cells and its level in the vaginal fluid is influenced by progesterone.

Bulla R, De Seta F, Radillo O, Agostinis C, Durigutto P, Pellis V, De Santo D, Crovella S, Tedesco F.

Mol Immunol. 2010 Nov-Dec;48(1-3):281-6. Epub 2010 Aug 21.

Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency.

Bossi F, Fischetti F, Regoli D, Durigutto P, Frossi B, Gobeil F Jr, Ghebrehiwet B, Peerschke EI, Cicardi M, Tedesco F.

J Allergy Clin Immunol. 2009 Dec;124(6):1303-10.e4. doi: 10.1016/j.jaci.2009.08.007

Posttransplant Ischemia-Reperfusion Injury In Transplanted Heart Is Prevented By A Minibody to the Fifth Component of Complement.

Ferraresso M, Macor P, Valente M, Barbera MD, D'Amelio F, Borghi O, Raschi E, Durigutto P, Meroni P, Tedesco F.

Transplantation. 2008 Nov 27;86(10):1445-1451.

Complement C1q and C8beta deficiency in an individual with recurrent bacterial meningitis and adult-onset systemic lupus erythematosus-like illness.

Pickering MC, Macor P, Fish J, Durigutto P, Bossi F, Petry F, Botto M, Tedesco F.

Rheumatology (Oxford). 2008 Oct;47(10):1588-9. Epub 2008 Aug

Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats.

Fischetti F, Durigutto P, Macor P, Marzari R, Carretta R, Tedesco F.

Arthritis Rheum. 2007 Apr;56(4):1187-97.

Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo.

Zauli G, Corallini F, Bossi F, Fischetti F, Durigutto P, Celeghini C, Tedesco F, Secchiero P.

Blood. 2007 Jul 15;110(2):536-43. Epub 2007 Mar 15.

The neutrophil-activating protein of Helicobacter pylori crosses endothelia to promote neutrophil adhesion in vivo.

Polenghi A, Bossi F, Fischetti F, Durigutto P, Cabrelle A, Tamassia N, Cassatella MA, Montecucco C, Tedesco F, de Bernard M.

J Immunol. 2007 Feb 1;178(3):1312-20.

Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor.

Fischetti F, Durigutto P, Pellis V, Debeus A, Macor P, Bulla R, Bossi F, Ziller F, Sblattero D, Meroni P, Tedesco F.

Blood. 2005 Oct 1;106(7):2340-6. Epub 2005 Jun 14.

Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation.

Fischetti F, Carretta R, Borotto G, Durigutto P, Bulla R, Meroni PL, Tedesco F.

Clin Exp Immunol. 2004 Feb;135(2):186-93.